ReviewJournal of controlled release : official journal of the Controlled Release Society2012
Challenges to effective cancer nanotheranostics.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics.Molecules (Basel, Switzerland) · 2022Review
- Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.Frontiers in pharmacology · 2022Review
- Responsive Polymer Brush Design and Emerging Applications for Nanotheranostics.Advanced healthcare materials · 2021Review
- Recent Advances in Porphyrin-Based Inorganic Nanoparticles for Cancer Treatment.International journal of molecular sciences · 2020Review
- The Local Atomic Structure of Colloidal Superparamagnetic Iron Oxide Nanoparticles for Theranostics in Oncology.Biomedicines · 2018Review
- Theranostic Nanoparticles for Tracking and Monitoring Disease State.SLAS technology · 2018Review
- Pro-apoptotic liposomes-nanobubble conjugate synergistic with paclitaxel: a platform for ultrasound responsive image-guided drug delivery.Scientific reports · 2018Article
- Remotely Triggered Nano-Theranostics For Cancer Applications.Nanotheranostics · 2017Article
- Rethinking cancer nanotheranostics.Nature reviews. Materials · 2017Article
- Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.Theranostics · 2016Review
- Theranostic CuS Nanoparticles Targeting Folate Receptors for PET Image-Guided Photothermal Therapy.Journal of materials chemistry. B · 2015Article
- A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- A biological perspective toward the interaction of theranostic nanoparticles with the bloodstream - what needs to be considered?Frontiers in chemistry · 2015Article
- Photodynamic therapy: one step ahead with self-assembled nanoparticles.Journal of biomedical nanotechnology · 2014Review
- Light-activatable gold nanoshells for drug delivery applications.AAPS PharmSciTech · 2014Review
- Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer.International journal of nanomedicine · 2014Article
- Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer.Frontiers in physiology · 2014Review
- Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles.Theranostics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Advances in nanotechnology for oncology will arise from an increased understanding of the interaction between nanomaterials and biological systems; refinement of multifunctional nanocomposites for applications such as simultaneous imaging and therapy (theranostics); and harnessing of the unique physicochemical properties arising from nanoscale effects which distinguish them from small-molecular-weight molecules in the detection and destruction of cancer cells with high selectivity and efficiency. The major challenges in successful clinical translation of tumor specific nanoparticle delivery include overcoming various biological barriers and demonstrating enhanced therapeutic efficacy over the current standard of care in the clinic. For many nanoparticle mediated theranostic applications, image guidance can play a crucial role not only in exploiting the cancer specific imaging capabilities of these novel particles, but in planning, targeting, monitoring and verifying treatment delivery, thus enhancing the safety and efficacy of these emerging procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.